A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique

Vaccine

Volumn 28, Issue 7, 2010, Pages 1717-1725

  Pietrella, Donatella ^a   Rachini, Anna ^a   Torosantucci, Antonella ^b   Chiani, Paola ^b   Brown, Alistair J P ^c   Bistoni, Francesco ^a   Costantino, Paolo ^d   Mosci, Paolo ^a   d'Enfert, Christophe ^e,f   Rappuoli, Rino ^d   Cassone, Antonio ^b   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^e INSTITUT PASTEUR   (France)

^f INRA USC 2019   (France)

Author keywords

Candida; In vivo imaging; MF59; Vaginal infection

Indexed keywords

BETA 1,3 GLUCAN MONOCLONAL ANTIBODY; BETA GLUCAN CONJUGATE VACCINE; FUNGUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; LUCIFERASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; IN VIVO STUDY; LUMINESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VAGINA DISCHARGE; VAGINITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; BETA-GLUCANS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; DIAGNOSTIC IMAGING; FEMALE; FUNGAL VACCINES; IMMUNIZATION, PASSIVE; MICE; POLYSORBATES; SQUALENE; VACCINES, CONJUGATE;

EID: 75249095379     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.021     Document Type: Article

References (52)

1. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 1 (2002) 7-14
2. Caston-Osorio J.J., Rivero A., and Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 32 Suppl. 2 (2008) S103-S109
3. Kibbler C. Defining invasive fungal infections in neutropenic or stem cell transplant patients. J Antimicrob Chemother 56 Suppl. 1 (2005) i12-i16
4. Fidel Jr. P.L., and Sobel J.D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 9 3 (1996) 335-348
5. Ringdahl E.N. Recurrent vulvovaginal candidiasis. Mol Med 103 2 (2006) 165-168
6. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 14 Suppl. 1 (1992) S148-S153
7. Sobel J.D. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Infect Dis Rep 4 6 (2002) 514-519
8. Spacek J., Buchta V., Jilek P., and Forstl M. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 131 2 (2007) 198-202
9. Fidel Jr. P.L., Lynch M.E., Conaway D.H., Tait L., and Sobel J.D. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun 63 2 (1995) 547-553
10. Leigh J.E., Barousse M., Swoboda R.K., Myers T., Hager S., Wolf N.A., et al. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 183 2 (2001) 277-285
11. Lynch M.E., Sobel J.D., and Fidel Jr. P.L. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 34 5 (1996) 337-339
12. Sobel J.D. Management of patients with recurrent vulvovaginal candidiasis. Drugs 63 11 (2003) 1059-1066
13. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 351 9 (2004) 876-883
14. Fidel Jr. P.L. The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models. Int Rev Immunol 21 6 (2002) 515-548
15. Fidel Jr. P.L. Immunity in vaginal candidiasis. Curr Opin Infect Dis 18 2 (2005) 107-111
16. Fidel Jr. P.L., Luo W., Steele C., Chabain J., Baker M., and Wormley Jr. F. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 67 6 (1999) 3135-3140
17. Babula O., Lazdane G., Kroica J., Ledger W.J., and Witkin S.S. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 37 5 (2003) 733-737
18. Babula O., Lazdane G., Kroica J., Linhares I.M., Ledger W.J., and Witkin S.S. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 40 9 (2005) 1258-1262
19. Chaim W., Foxman B., and Sobel J.D. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 176 3 (1997) 828-830
20. Fidel Jr. P.L. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 57 1 (2007) 2-12
21. De Bernardis F., Adriani D., Lorenzini R., Pontieri E., Carruba G., and Cassone A. Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection. Infect Immun 61 4 (1993) 1500-1508
22. De Bernardis F., Boccanera M., Adriani D., Spreghini E., Santoni G., and Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 65 8 (1997) 3399-3405
23. De Bernardis F., Liu H., O'Mahony R., La Valle R., Bartollino S., Sandini S., et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195 1 (2007) 149-157
24. De Bernardis F., Agatensi L., Ross I.K., Emerson G.W., Lorenzini R., Sullivan P.A., et al. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J Infect Dis 161 6 (1990) 1276-1283
25. Cassone A., De Bernardis F., and Santoni G. Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect Immun 75 10 (2007) 4675-4686
26. Cassone A., and Torosantucci A. Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines 5 6 (2006) 859-867
27. De Bernardis F., Boccanera M., Adriani D., Girolamo A., and Cassone A. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 70 5 (2002) 2725-2729
28. Moragues M.D., Omaetxebarria M.J., Elguezabal N., Sevilla M.J., Conti S., Polonelli L., et al. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 71 9 (2003) 5273-5279
29. Polonelli L., De Bernadis F., Conti S., Boccanera M., Magliani W., Gerloni M., et al. Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 156 5 (1996) 1880-1885
30. Polonelli L., De Bernardis F., Conti S., Boccanera M., Gerloni M., Morace G., et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152 6 (1994) 3175-3182
31. Polonelli L., Magliani W., Conti S., Bracci L., Lozzi L., Neri P., et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 71 11 (2003) 6205-6212
32. Santoni G., Boccanera M., Adriani D., Lucciarini R., Amantini C., Morrone S., et al. Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect Immun 70 9 (2002) 4791-4797
33. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202 5 (2005) 597-606
34. de Bernardis F., Santoni G., Boccanera M., Spreghini E., Adriani D., Morelli L., et al. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 68 6 (2000) 3297-3304
35. Fidel Jr. P.L., Lynch M.E., and Sobel J.D. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun 61 5 (1993) 1990-1995
36. Hamad M., Muta'eb E., Abu-Shaqra Q., Fraij A., Abu-Elteen K., and Yasin S.R. Utility of the oestrogen-dependent vaginal candidosis murine model in evaluating the efficacy of various therapies against vaginal Candida albicans infection. Mycoses 49 2 (2006) 104-108
37. Enjalbert B., Rachini A., Vediyappan G., Pietrella D., Spaccapelo R., Vecchiarelli A., et al. A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections. Infect Immun 77 11 (2009) 4847-4858
38. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A.S., Liu Y., et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4 4 (2009) e5392
39. Moreno-Ruiz E., Ortu G., de Groot P.W., Cottier F., Loussert C., Prévost M.C., et al. The GPI-modified proteins Pga59 and Pga62 of Candida albicans are required for cell wall integrity. Microbiology 155 6 (2009) 2004-2020
40. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., and Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11 3 (2005) 435-443
41. Raska M., Belakova J., Horynova M., Krupka M., Novotny J., Sebestova M., et al. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 46 5 (2008) 411-420
42. Saavedra M., Taylor B., Lukacs N., and Fidel Jr. P.L. Local production of chemokines during experimental vaginal candidiasis. Infect Immun 67 11 (1999) 5820-5826
43. Steele C., Ozenci H., Luo W., Scott M., and Fidel Jr. P.L. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 37 4 (1999) 251-259
44. Wozniak K.L., Wormley Jr. F.L., and Fidel Jr. P.L. Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect Immun 70 10 (2002) 5790-5799
45. De Bernardis F., Lucciarini R., Boccanera M., Amantini C., Arancia S., Morrone S., et al. Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis. Infect Immun 74 7 (2006) 4282-4294
46. Yordanov M., Dimitrova P., Danova S., and Ivanovska N. Candida albicans double-stranded DNA can participate in the host defense against disseminated candidiasis. Microbes Infect 7 2 (2005) 178-186
47. Bailey D.A., Feldmann P.J., Bovey M., Gow N.A., and Brown A.J. The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J Bacteriol 178 18 (1996) 5353-5360
48. Hoyer L.L., Payne T.L., Bell M., Myers A.M., and Scherer S. Candida albicans ALS3 and insights into the nature of the ALS gene family. Curr Genet 33 6 (1998) 451-459
49. Phan Q.T., Myers C.L., Fu Y., Sheppard D.C., Yeaman M.R., Welch W.H., et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 5 3 (2007) e64
50. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6 5 (2007) 699-710
51. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106 10 (2009) 3877-3882
52. Granoff D.M., McHugh Y.E., Raff H.V., Mokatrin A.S., and Van Nest G.A. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect Immun 65 5 (1997) 1710-1715